Edgewise Therapeutics
EWTX
90 hedge funds and large institutions have $594M invested in Edgewise Therapeutics in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 16 reducing their positions, and 14 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 16
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
17% more capital invested
Capital invested by funds: $505M → $594M (+$88.4M)
2.18% less ownership
Funds ownership: 107.31% → 105.13% (-2.2%)
4% less funds holding
Funds holding: 94 → 90 (-4)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
50% less call options, than puts
Call options by funds: $25K | Put options by funds: $50K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$9.4M |
| 2 |
BlackRock
New York
|
+$7.11M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.17M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$15.6M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$2.99M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$1.69M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$1.21M |
| 5 |
Millennium Management
New York
|
-$1.09M |
EWTX Hedge Fund Activity: Q4 2022 in Review
90 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q4 2022, worth a combined $594M — up 17% from $505M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of EWTX and 11 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 44 added.
The largest buyer was Goldman Sachs, adding an estimated $9.4M. The largest seller was Janus Henderson Group, cutting an estimated $15.6M.
- 90 institutional investors held Edgewise Therapeutics (EWTX) as of Q4 2022, down from 94 in Q3 2022.
- Funds reported $594M of Edgewise Therapeutics stock for Q4 2022, up 17% quarter-over-quarter.
- 11 funds opened new Edgewise Therapeutics positions in Q4 2022 and 14 closed out, a net change of -3 holders.
- The largest Edgewise Therapeutics buyer in Q4 2022 was Goldman Sachs, an estimated $9.4M added.
- The largest Edgewise Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2022.